Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Silymarin137 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00243 | 35170400 | Bioengineered | Hepatoprotective mechanism of Silybum marianum on nonalcoholic fatty liver disease based on network pharmacology and experimental verification. | 2022 | Details |
| A01214 | 34827721 | Biomolecules | The Effect of Mycotoxins and Silymarin on Liver Lipidome of Mice with Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A01923 | 34560694 | Eur J Gastroenterol Hepatol | Healthcare practitioners' diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional survey. | 2022 | Details |
| A02313 | 34423182 | ACS Omega | Effect of Silymarin and Quercetin in a Miniaturized Scaffold in Wistar Rats against Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A02443 | 34370218 | Clin J Gastroenterol | Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis. | 2021 | Details |
| A02905 | 34201527 | Antioxidants (Basel) | Ethyl Acetate Fraction of Amomum villosum var. xanthioides Attenuates Hepatic Endoplasmic Reticulum Stress-Induced Non-Alcoholic Steatohepatitis via Improvement of Antioxidant Capacities. | 2021 | Details |
| A03200 | 34092291 | Chin J Nat Med | Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α. | 2021 | Details |
| A03906 | 33824122 | Pak J Pharm Sci | Antioxidant characteristics and hepatoprotective effects of a formula derived from Maydis stigma, Nelumbo nucifera and Taraxacum officinale against carbon tetrachloride-induced hepatic damage in rats. | 2020 | Details |
| A04028 | 33785007 | BMC Complement Med Ther | Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats. | 2021 | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | 2021 | Details |
| A04097 | 33761646 | Medicine (Baltimore) | The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. | 2021 | Details |
| A04471 | 33603899 | Maedica (Bucur) | Triple Antioxidant Therapy, an Alternative for Patients with Chronic Liver Disease - A Prospective Multicenter Interventional Study. | 2020 | Details |
| A04524 | 33587330 | Phytother Res | Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions. | 2021 | Details |
| A04670 | 33546130 | Nutrients | Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A04735 | 33520810 | J Diabetes Metab Disord | Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease. | 2020 | Details |
| A04829 | 33491528 | J Diet Suppl | The Effects of Vitamin E, Silymarin and Carnitine on the Metabolic Abnormalities Associated with Nonalcoholic Liver Disease. | 2021 | Details |
| A05001 | 33418491 | Nutrition | Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis. | 2020 | Details |
| A05903 | 33080906 | Medicina (Kaunas) | Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients. | 2020 | Details |
| A06217 | 32964201 | JHEP Rep | The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. | 2020 | Details |
| A06327 | 32927776 | Nutrients | New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. | 2020 | Details |
| A06984 | 32673798 | Mol Metab | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. | 2020 | Details |
| A08247 | 32189355 | J Food Biochem | Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice. | 2020 | Details |
| A08380 | 32134732 | J Basic Clin Physiol Pharmacol | Silymarin: not just another antioxidant. | 2020 | Details |
| A08479 | 32093158 | Nutrients | Beneficial Effects of Lactobacillus plantarum Strains on Non-Alcoholic Fatty Liver Disease in High Fat/High Fructose Diet-Fed Rats. | 2020 | Details |
| A08548 | 32065376 | Adv Ther | Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. | 2020 | Details |
| A08765 | 31993304 | Acta Pharm Sin B | Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. | 2019 | Details |
| A08926 | 31935496 | J Ethnopharmacol | A review of Penthorum chinense Pursh for hepatoprotection: Traditional use, phytochemistry, pharmacology, toxicology and clinical trials. | 2020 | Details |
| A09934 | 31554528 | Br J Nutr | Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. | 2020 | Details |
| A09985 | 31536511 | PLoS One | Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. | 2019 | Details |
| A10230 | 31420525 | J Pharmacol Exp Ther | A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model. | 2019 | Details |
| A10808 | 31178720 | Front Pharmacol | Role of Natural Phenolics in Hepatoprotection: A Mechanistic Review and Analysis of Regulatory Network of Associated Genes. | 2019 | Details |
| A11365 | 30920975 | Eur J Gastroenterol Hepatol | Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. | 2019 | Details |
| A11836 | 30713255 | Biol Pharm Bull | Preventive Effect of Citrus aurantium Peel Extract on High-Fat Diet-Induced Non-alcoholic Fatty Liver in Mice. | 2019 | Details |
| A12512 | 30414175 | J Sci Food Agric | Triticum aestivum ethanolic extract improves non-alcoholic fatty liver disease in mice fed a choline-deficient or high-fat diet. | 2019 | Details |
| A12972 | 30201879 | Diseases | Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. | 2018 | Details |
| A12993 | 30191499 | Dig Dis Sci | Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway. | 2018 | Details |
| A13022 | 30176941 | J Nanobiotechnology | Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD. | 2018 | Details |
| A13089 | 30142943 | Nutrients | Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. | 2018 | Details |
| A13300 | 30042374 | Int J Mol Sci | Silibinin Ameliorates O-GlcNAcylation and Inflammation in a Mouse Model of Nonalcoholic Steatohepatitis. | 2018 | Details |
| A13321 | 30032630 | Rev Esp Enferm Dig | Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease. | 2018 | Details |
| A13989 | 29655677 | Phytomedicine | An in vitro and in vivo study of a 4-herb formula on the management of diet-induced metabolic syndrome. | 2018 | Details |
| A14226 | 29515630 | Iran J Pathol | Clinical Manifestations and Diagnosis of Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A14650 | 29309065 | World J Gastroenterol | Silymarin: An option to treat non-alcoholic fatty liver disease. | 2017 | Details |
| A14731 | 29268106 | J Nutr Biochem | Food components with antifibrotic activity and implications in prevention of liver disease. | 2017 | Details |
| A14773 | 29245314 | Medicine (Baltimore) | The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials. | 2017 | Details |
| A15302 | 28973994 | Nutrients | Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver. | 2017 | Details |
| A15315 | 28970254 | FASEB J | Silybin inhibits NLRP3 inflammasome assembly through the NAD+/SIRT2 pathway in mice with nonalcoholic fatty liver disease. | 2018 | Details |
| A15380 | 28937599 | Nutrients | Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. | 2017 | Details |
| A15459 | 28895929 | Nutrients | Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis. | 2017 | Details |
| A15921 | 28652427 | In Vivo | A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells. | 2018 | Details |
| A15925 | 28648927 | J Ethnopharmacol | Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation. | 2017 | Details |
| A16212 | 28505074 | Nutrients | NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet. | 2017 | Details |
| A16332 | 28454924 | Toxicol Appl Pharmacol | Dual effect of silymarin on experimental non-alcoholic steatohepatitis induced by irinotecan. | 2017 | Details |
| A16395 | 28419855 | Clin Gastroenterol Hepatol | A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. | 2017 | Details |
| A16488 | 28358980 | Cochrane Database Syst Rev | Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. | 2017 | Details |
| A16803 | 28164196 | Food Funct | Preventive effect of Silibinin in combination with Pu-erh tea extract on non-alcoholic fatty liver disease in ob/ob mice. | 2017 | Details |
| A16856 | 28125040 | Molecules | Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. | 2017 | Details |
| A16911 | 28098838 | Molecules | Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD. | 2017 | Details |
| A17585 | 27733832 | Front Pharmacol | Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor. | 2016 | Details |
| A17936 | 27468193 | World J Gastroenterol | Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells. | 2016 | Details |
| A18175 | 27308649 | J Gastrointestin Liver Dis | Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists. | 2016 | Details |
| A18399 | 27158393 | Am J Transl Res | Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). | 2016 | Details |
| A18893 | 26881746 | PLoS One | Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. | 2016 | Details |
| A18954 | 26852185 | Br J Clin Pharmacol | The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. | 2016 | Details |
| A19650 | 26436447 | Liver Int | Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. | 2015 | Details |
| A19763 | 26367736 | Eur Rev Med Pharmacol Sci | Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. | 2015 | Details |
| A19993 | 26219393 | Curr Med Chem | The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular). | 2015 | Details |
| A20791 | 25732561 | Drugs R D | Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. | 2015 | Details |
| A20963 | 25617046 | Expert Rev Gastroenterol Hepatol | Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. | 2015 | Details |
| A21148 | 25514914 | Rev Recent Clin Trials | Phytotherapy and NAFLD--from goals and challenges to clinical practice. | 2014 | Details |
| A21240 | 25460293 | Horm Mol Biol Clin Investig | Nutrition: a promising route for prevention and management of obesity-related nonalcoholic fatty liver disease. | 2014 | Details |
| A21327 | 25404123 | Drugs R D | In vivo efficacy study of milk thistle extract (ETHIS-094™) in STAM™ model of nonalcoholic steatohepatitis. | 2014 | Details |
| A21497 | 25274101 | Br J Nutr | Non-alcoholic fatty liver disease: need for a balanced nutritional source. | 2014 | Details |
| A22527 | 24490006 | Caspian J Intern Med | Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. | 2014 | Details |
| A23085 | 24053454 | BMC Gastroenterol | The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. | 2013 | Details |
| A23107 | 24036369 | Int Immunopharmacol | Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway. | 2013 | Details |
| A23699 | 23556042 | World J Hepatol | Silymarin in non alcoholic fatty liver disease. | 2013 | Details |
| A23725 | 23532271 | Braz J Med Biol Res | Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. | 2013 | Details |
| A24238 | 23087748 | Hepat Mon | Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. | 2012 | Details |
| A24289 | 23036186 | Dig Liver Dis | A new approach to facilitate diagnosis of nonalcoholic fatty liver disease through a galactose single point method in rats with fatty liver. | 2012 | Details |
| A24468 | 22864747 | Arch Pharm Res | Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats. | 2012 | Details |
| A24597 | 22710359 | Int J Mol Med | Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells. | 2012 | Details |
| A24668 | 22633099 | Transl Res | Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. | 2012 | Details |
| A24916 | 22364002 | Eksp Klin Gastroenterol | [Study of clinical efficiency of essential phospholipids and silymarin combination in nonalcoholic and alcoholic steatohepatitis]. | 2011 | Details |
| A24933 | 22343419 | Free Radic Biol Med | Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. | 2012 | Details |
| A25070 | 22197629 | Dig Liver Dis | Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. | 2011 | Details |
| A25425 | 21865319 | Drug Metab Dispos | Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. | 2011 | Details |
| A25510 | 21755261 | Braz J Med Biol Res | Effect of silybin on high-fat-induced fatty liver in rats. | 2011 | Details |
| A25684 | 21547049 | J Ayurveda Integr Med | A study of standardized extracts of Picrorhiza kurroa Royle ex Benth in experimental nonalcoholic fatty liver disease. | 2010 | Details |
| A26281 | 20734480 | Eksp Klin Gastroenterol | [Use of Legalon in non-alcoholic fatty liver disease]. | 2010 | Details |
| A27154 | 19073452 | Orv Hetil | [Silymarin in the treatment of chronic liver diseases: past and future]. | 2008 | Details |
| A28165 | 16231594 | Eur Rev Med Pharmacol Sci | The treatment of NAFLD. | 2006 | Details |
| A28238 | 15990709 | Minerva Gastroenterol Dietol | [Effects of a new pharmacological complex (silybin + vitamin-E + phospholipids) on some markers of the metabolic syndrome and of liver fibrosis in patients with hepatic steatosis. Preliminary study]. | 2005 | Details |
| A32164 | 29068700 | Nutr Cancer | Silibinin Reduces the Impact of Obesity on Invasive Liver Cancer. | 2017 | Details |
| A34717 | 22797645 | JAMA | Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. | 2012 | Details |
| A35163 | 21560654 | Eksp Klin Gastroenterol | [Hepatoprotective properties of silymarin]. | 2011 | Details |
| A37065 | 16535923 | Recenti Prog Med | [Oxidative stress in metabolic syndrome and nonalcoholic steatohepatitis. Is it possible a role for vitamins in clinical practice?]. | 2006 | Details |
| A38085 | 12192203 | J Clin Gastroenterol | Management of nonalcoholic steatohepatitis: an analytic review. | 2002 | Details |
| A42262 | 35047045 | Evid Based Complement Alternat Med | Development of a Hepatoprotective Herbal Drug from Turnera diffusa. | 2022 | Details |
| A42358 | 34772595 | Nutrition | Authors' response re. "May Silymarin be selectively considered for nonalcoholic fatty liver disease without elevated transaminases?" | 2021 | Details |